Bcr-Abl tyrosine-kinase inhibitor

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality was discovered by Janet Rowley during 1972 and is a consequence of f...
Found on http://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor
No exact match found